Literature DB >> 14752276

Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation.

Maddalena Donzelli1, Luca Busino, Massimo Chiesa, Dvora Ganoth, Avram Hershko, Giulio F Draetta.   

Abstract

We have recently demonstrated that regulation of Cdc25A protein abundance during S phase and in response to DNA damage is mediated by SCF(betaTrCP) activity. Based on sequence homology of known betaTrCP substrates, we found that Cdc25A contains a conserved motif (DSG), phosphorylation of which is required for interaction with betaTrCP.1 Here, we show that phosphorylation at Ser 82 within the DSG motif anchors Cdc25A to betaTrCP and that Chk1-dependent phosphorylation at Ser 76 affects this interaction as well as betaTrCP-dependent degradation. We propose that a hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation. According to our model, phosphorylation at Ser 76 is a "priming" step required for Ser 82 phosphorylation, which in turn allows recruitment of Cdc25A by betaTrCP and subsequent betaTrCP-dependent degradation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752276

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1.

Authors:  David V Hansen; Alexander V Loktev; Kenneth H Ban; Peter K Jackson
Journal:  Mol Biol Cell       Date:  2004-10-06       Impact factor: 4.138

2.  Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Authors:  Dipankar Ray; Yasuhisa Terao; Dipali Nimbalkar; Li-Hao Chu; Maddalena Donzelli; Tateki Tsutsui; Xianghong Zou; Asish K Ghosh; John Varga; Giulio F Draetta; Hiroaki Kiyokawa
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 3.  Ubiquitin and SUMO systems in the regulation of mitotic checkpoints.

Authors:  Gustavo J Gutierrez; Ze'ev Ronai
Journal:  Trends Biochem Sci       Date:  2006-05-02       Impact factor: 13.807

Review 4.  The role of Cdc25A in the regulation of cell proliferation and apoptosis.

Authors:  Tao Shen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2012-07       Impact factor: 2.505

5.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

6.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

7.  Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction.

Authors:  Y Honaker; H Piwnica-Worms
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

8.  Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor.

Authors:  Sabyasachi Bhattacharya; Wei-Chun HuangFu; Jianghuai Liu; Sudhakar Veeranki; Darren P Baker; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

9.  GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

Authors:  Tiebang Kang; Yongkun Wei; Yuchi Honaker; Hiroshi Yamaguchi; Ettore Appella; Mien-Chie Hung; Helen Piwnica-Worms
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

10.  Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.

Authors:  Jianping Jin; Xiaolu L Ang; Xin Ye; Mark Livingstone; J Wade Harper
Journal:  J Biol Chem       Date:  2008-05-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.